Therefore, triggering the immunoreceptor RIG-I in NK cells could offer an improved approach to exploit the anti-tumour effects of membrane-bound TRAIL, although conflicting results have been reported on the relevance of NK cells in RIG-I-based immunotherapy. The gene discussed is RIGI; the disease is neoplasm.